Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hyperparathyroidism

Hyperparathyroidism

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperparathyroidism

46 trials tracked for Hyperparathyroidism: 18 in phase 3 or 4 and 3 with published results. The most-cited published study has 308 citations.

46Trials tracked
18Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 9 Phase 3 9 Phase 2 8 Phase 1 4 Other / NA 16
  1. Phase 3 Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet Completed · 308 cited
  2. Phase 3 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Completed · 19 cited
  3. Phase 4 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed · 4 cited
  4. Phase 4 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed
  5. Phase 4 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed
  6. Phase 4 20070360 Incident Dialysis Completed
Show 40 more trials
  1. Phase 4 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed
  2. Phase 4 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed
  3. Phase 4 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed
  4. Phase 4 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed
  5. Phase 4 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed
  6. Phase 3 Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Completed
  7. Phase 3 Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Completed
  8. Phase 3 E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events Completed
  9. Phase 3 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Completed
  10. Phase 3 Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease Completed
  11. Phase 3 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism Completed
  12. Phase 3 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed
  13. Phase 2 Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Completed
  14. Phase 2 Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism Completed
  15. Phase 2 Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis Completed
  16. Phase 2 Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease Completed
  17. Phase 2 Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) Completed
  18. Phase 2 Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients Completed
  19. Phase 2 Studies of Elevated Parathyroid Activity Completed
  20. Phase 2 Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder Completed
  21. Phase 1 A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 Completed
  22. Phase 1 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Completed
  23. Phase 1 Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease Completed
  24. Phase 1 7 Day Continuous Parathyroid Hormone IV Infusion Completed
  25. N/A Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous Completed
  26. N/A Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis Completed
  27. N/A Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice Completed
  28. N/A FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease Completed
  29. N/A Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism Completed
  30. N/A Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience Completed
  31. N/A Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) Completed
  32. N/A Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy Completed
  33. N/A Vascular Risk After Kidney Transplantation Completed
  34. N/A Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy Completed
  35. N/A Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients Completed
  36. N/A Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years Completed
  37. N/A Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) Completed
  38. N/A Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation Completed
  39. N/A The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study Completed
  40. N/A Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism Completed

Showing the 46 most-cited and recently-updated of 46 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hyperparathyroidism: what the trials found

Cinacalcet has demonstrated significant efficacy in reducing parathyroid hormone (PTH) levels and managing mineral metabolism. Trials showed a 30% reduction in mean PTH at both 6 months 3 and 12 months 3, with specific cohorts achieving PTH targets of $\leq$ 300 pg/mL [1, 3]. Additionally, Cinacalcet was associated with significant reductions in serum phosphorus 14 and absolute decreases in PTH values 8. Clinical outcomes included a high percentage of patients achieving corrected total serum calcium below 10.2 mg/dL 14, while some data indicated improvements in Ca x P values 7 and specific targets for calcium and phosphorus levels 7.

Etelcalcetide demonstrated significant reductions in parathyroid hormone across multiple studies, with high percentages of patients achieving a $\geq$ 30% reduction from baseline [10, 20, 21] and a $\geq$ 50% reduction [10, 12, 21]. In pre-dialysis populations, Etelcalcetide showed superior results in reducing mean PTH compared to other cohorts [12, 20].

Paricalcitol (including Zemplar) demonstrated consistent ability to reduce PTH levels. Trials reported high percentages of patients achieving a $\geq$ 30% reduction in PTH [4, 5, 11] and significant numbers reaching the target range of 150-300 pg/mL [4, 11]. Paricalcitol was also associated with lower rates of hypercalcemia compared to some benchmarks 2, and specific trials showed it could achieve targets for PTH without inducing hypercalcemia in a subset of patients 18.

Recent results — preliminary, needs further review

  • Sensipar (Cinacalcet HCl) showed a -6.5% change from baseline in serum calcium, -1.1% in phosphorus, and -6.9% in Ca x P; however, these findings are not yet corroborated.
  • 68Ga-Dotatate is currently under investigation but results are not yet corroborated.

For the clinician treating this condition

  • Cinacalcet and Etelcalcetide are established options for achieving significant reductions in PTH (30-50%+) and reaching specific target thresholds ($\leq$ 300 pg/mL).
  • Paricalcitol is an established intervention for reducing PTH levels and managing the associated mineral balance, with high success rates in achieving $\geq$ 30% reduction from baseline.
  • Cinacalcet has been shown to effectively lower serum phosphorus and manage corrected total serum calcium in clinical settings.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pre-transplant parathyroidectomy may reduce graft loss while maintaining comparable long-term renal function
Diabetes & Endocrinology Meta-analysis
Pre-transplant parathyroidectomy may reduce graft loss while maintaining comparable long-term renal function Timing of surgery for kidney transplant candidates impacts graft survival
This systematic review of 8 observational studies involving 4355 patients examined pre-transplant versus post-transplant parathyroidectomy f…
Surgery before a kidney transplant might help keep the new organ working longer, but it carries different risks for patient safety and recov…
Frontiers Jul 3, 2026
Surgery remains the only curative treatment for primary hyperparathyroidism, review confirms
Diabetes & Endocrinology Sys. Review
Surgery remains the only curative treatment for primary hyperparathyroidism, review confirms Surgery Remains the Only Cure for Hyperparathyroidism
This narrative review on hyperparathyroidism confirms that surgery is the only curative treatment for primary HPT. The field has shifted fro…
A new review confirms surgery is the only cure for hyperparathyroidism, with minimally invasive techniques now standard.
Frontiers Jun 26, 2026
Case report suggests hemorrhagic fever with renal syndrome may trigger secondary hyperparathyroidism
Diabetes & Endocrinology Sys. Review
Case report suggests hemorrhagic fever with renal syndrome may trigger secondary hyperparathyroidism Kidney Failure Causes Hormone Surge in Rare Virus Recovery
This case report describes a patient with hemorrhagic fever with renal syndrome in whom secondary hyperparathyroidism was suspected to be tr…
A rare virus causing sudden kidney failure may unexpectedly spike hormone levels during recovery, revealing a hidden complication doctors ra…
Frontiers May 9, 2026
NIRAF imaging associated with improved parathyroid identification during thyroidectomy in retrospective study
Diabetes & Endocrinology Cohort
NIRAF imaging associated with improved parathyroid identification during thyroidectomy in retrospective study Can a special light help surgeons spot tiny glands during thyroid surgery?
A retrospective cohort study of 349 patients undergoing total thyroidectomy found NIRAF-assisted identification was associated with more gla…
A special light helps surgeons spot more tiny calcium-controlling glands during thyroid surgery, leading to higher hormone levels right afte…
Frontiers Apr 8, 2026

Questions about Hyperparathyroidism

Is surgery the only curative treatment for primary Hyperparathyroidism?

Surgery (parathyroidectomy) is currently the only curative treatment for primary hyperparathyroidism.

Full answer →
Does NIRAF imaging help identify glands during thyroidectomy for Hyperparathyroidism?

NIRAF imaging is an emerging technology that helps surgeons identify and preserve parathyroid glands during thyroid surgery by using near-infrared light.

Full answer →
Is surgery the only way to cure primary Hyperparathyroidism?

Surgery is currently the only known way to cure primary hyperparathyroidism.

Full answer →